Morning Briefing
Summaries of health policy coverage from major news organizations
Some Question If HHS Nominee, Who Has Ties To Industry, Will Really Combat Pharma 'Greed'
During Alex Azar's tenure at Eli Lilly, the drugmaker instituted steep price increases on insulin and other medicines.
The New York Times: He Raised Drug Prices At Eli Lilly. Can He Lower Them For The U.S.?
Alex M. Azar II, President Trump’s nominee to lead the Department of Health and Human Services, has expressed concern about the soaring cost of prescription drugs for many consumers. This week, Mr. Azar, a former pharmaceutical executive, is expected to face tough questions at a Senate confirmation hearing over why his own company raised prices. Democratic senators say that, as a top manager at Eli Lilly and Company, he was responsible for steep increases on insulin and other drugs. How he would now tackle that problem as secretary, along with the future of the Affordable Care Act, promises to dominate the hearings. (Pear, 11/26)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
